uniQure (NASDAQ:QURE) Stock Price Expected to Rise, HC Wainwright Analyst Says

uniQure (NASDAQ:QURE) had its target price hoisted by investment analysts at HC Wainwright from $25.00 to $70.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 356.92% from the stock’s current price. HC Wainwright also issued estimates for uniQure’s FY2029 earnings at $18.47 EPS.

Several other research analysts have also recently issued reports on the company. Leerink Partners raised their price objective on uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 11th. Wells Fargo & Company raised shares of uniQure from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 10th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $24.00 price objective on shares of uniQure in a report on Tuesday, January 21st. The Goldman Sachs Group raised their target price on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a report on Thursday, December 12th. Finally, Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $40.00.

uniQure Stock Down 3.0 %

NASDAQ:QURE opened at $15.32 on Monday. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a twelve month low of $3.73 and a twelve month high of $19.18. The company has a market cap of $746.70 million, a PE ratio of -3.09 and a beta of 0.41. The company’s 50 day moving average is $13.31 and its two-hundred day moving average is $8.84.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. Analysts anticipate that uniQure will post -3.74 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 3,418 shares of uniQure stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares in the company, valued at $4,562,091.45. The trade was a 0.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.74% of the company’s stock.

Institutional Trading of uniQure

Several institutional investors have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. lifted its position in shares of uniQure by 9.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after buying an additional 969 shares in the last quarter. Sanders Morris Harris LLC raised its position in uniQure by 50.0% during the fourth quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company’s stock worth $1,803,000 after acquiring an additional 34,034 shares during the period. FNY Investment Advisers LLC purchased a new position in uniQure during the fourth quarter valued at $88,000. Franklin Resources Inc. acquired a new stake in shares of uniQure in the third quarter valued at about $7,360,000. Finally, Geode Capital Management LLC increased its stake in shares of uniQure by 1.3% during the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock worth $2,509,000 after purchasing an additional 6,362 shares in the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.